KindlyMD (NASDAQ:NAKA) CEO David Bailey Acquires 31,500 Shares

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey acquired 31,500 shares of KindlyMD stock in a transaction dated Tuesday, May 26th. The shares were acquired at an average price of $5.58 per share, with a total value of $175,770.00. Following the completion of the purchase, the chief executive officer owned 3,015,528 shares in the company, valued at approximately $16,826,646.24. The trade was a 1.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

KindlyMD Price Performance

KindlyMD stock opened at $5.40 on Thursday. The firm has a 50-day moving average of $8.31 and a 200-day moving average of $13.24. KindlyMD, Inc. has a one year low of $4.50 and a one year high of $1,120.00. The company has a market cap of $93.98 million, a price-to-earnings ratio of -0.13 and a beta of 17.12.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%.The business had revenue of $2.68 million for the quarter. As a group, sell-side analysts expect that KindlyMD, Inc. will post -16.8 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on NAKA shares. TD Cowen started coverage on shares of KindlyMD in a research note on Friday, April 10th. They set a “buy” rating and a $40.00 price objective on the stock. B. Riley Financial lowered their price objective on shares of KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Weiss Ratings upgraded shares of KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Maxim Group lowered their price objective on shares of KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Finally, Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, KindlyMD currently has a consensus rating of “Hold” and an average price target of $30.00.

Institutional Trading of KindlyMD

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in shares of KindlyMD by 76.2% during the 2nd quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock worth $484,000 after buying an additional 8,386 shares during the period. Osaic Holdings Inc. bought a new stake in shares of KindlyMD during the 2nd quarter worth about $215,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of KindlyMD during the 3rd quarter worth about $369,000. Tower Research Capital LLC TRC boosted its holdings in shares of KindlyMD by 1,638.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after buying an additional 31,245 shares during the period. Finally, CI Investments Inc. bought a new stake in shares of KindlyMD during the 3rd quarter worth about $995,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.